Search

file (10) (1)

OBI Information

News

HOMEWhat’s NewNews

2024.Nov.07

Corporate

OBI Pharma Invited to Speak at World ADC Conference Innovative Linker Technology and GlycOBI® ADC Platform Capture Global Attention

2024.Oct.27

Corporate

OBI Pharma to Showcase Research Achievements and Cutting Edge ADC Platform Technology
Frequent Speaking Engagements at Prestigious International Conferences

2024.Oct.27

Corporate

Sustainability

OBI Pharma and Fu Jen Catholic University Sign Industry-Academia Collaboration MOU
Advancing Biotechnology Innovation and Developing Young Talent

2024.Oct.27

Corporate

Sustainability

OBI volunteers at a breast cancer patient event Showcasing our commitment to patients and to new drug development.

2024.Oct.13

Corporate

Ascentawits Pharma announced the interim analysis results of the AST-3424 Phase II clinical efficacy and safety study in advanced HCC at the 2024 CSCO conference

2024.Sep.24

Corporate

Award & Certification​

OBI-992 Shortlisted as the Most Promising Clinical Candidate in the 11th Annual World ADC Awards

2024.Aug.22

Corporate

The 2nd World ADC Linker & Conjugation Summit – OBI Pharma Presents Results on Patented Enzyme - EndoSymeOBI® - for ADCs

2024.Aug.07

Corporate

OBI-992 has been approved by US FDA for Orphan Drug Designation for the treatment of gastric cancer

2024.Jul.30

Corporate

OBI Pharma: An Exciting Launching Pad for Young Scientists

2024.Jul.29

Corporate

OBI’s Proprietary ADC Platform GlycOBI® Seeks Collaborative Partnerships for Development

Announcements

Latest announcements

Events

Latest events